Oncgnostics
Jena
About Oncgnostics
oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable in vitro diagnostic (=IVD) tests for screening, therapeutic decisions and follow-up care in cancer diagnostics. The diagnostic tests developed by oncgnostics are based on DNA regions specifically methylated in precancerous and carcinoma cells. These marker regions are detected using well-established PCR-based technologies, which can be performed in routine molecular diagnostics laboratories with standard equipment. oncgnostics has identified novel markers for detecting cervical precancerous lesions and carcinomas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Last round: Corporate Round (Sep 2023)
- Website: oncgnostics.com
- Phone: 49 3641 933544
Industries & Categories
Biotechnology, Health Diagnostics, Medical, Robotics
Social Profiles
Canonical: https://fsome.com/organization/oncgnostics-3197489 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.